PAC0015PR: Pancreatic Ductal Adenocarcinoma

TRACE-PDTX platform


Patient
Sex Male
Age at Time of Collection 66
Race / Ethnicity / Not Specified
Patient Tumor
Histology Pancreatic Ductal Adenocarcinoma
Primary Tissue pancreas
Collection Site pancreas
Tumor Type Primary
Grade Not specified
Stage cT4NxM1 ( Classification: TNM staging system)
PDX model Engraftment
Host Strain Name Site Type Material Material Status Passage
NMRI nude interscapular fat pad heterotopic tissue biopsy fresh 0, 1, 2, 3, 4
Model Quality Control
Technique Description Passage
Histology high concordance between xenograft and patient tumour 0,1,2,3,4
Fingerprinting high concordance between xenograft and patient tumour 0,1,2,3,4
Collection (Current Model)
Age 66
Diagnosis Pancreatic Ductal Adenocarcinoma
Type Primary
PDX Mouse PAC0015PR
Collection Site pancreas
Sex Male
Race / Ethnicity Not specified / Not Specified
Date Regimen Started Regimen Dose Best Response Duration (Months)
Jan 14 Cisplatin and FU-LV regimen Cisplatin, 50 mg/m2 on day 1, then De Gramont schedule on day 1-2: levofolic acid, 100 mg/m2 and 5-FU, 400 mg/m2 (bolus), at day 1 and 600 mg/m2 continuos infusion on day 1-2. All repeated every 3 weeks / Cisplatin, 50 mg/m2 on day 1, then De Gramont schedule on day 1-2: levofolic acid, 100 mg/m2 and 5-FU, 400 mg/m2 (bolus), at day 1 and 600 mg/m2 continuos infusion on day 1-2. All repeated every 3 weeks Progressive Disease 2.0 / 2.0
Apr 14 Paclitaxel 80mg/m2 weekly Progressive Disease 3.0
Nov 13 FU-LV regimen and Cisplatin Cisplatin, 50 mg/m2 on day 1, then De Gramont schedule on day 1-2: levofolic acid, 100 mg/m2 and 5-FU, 400 mg/m2 (bolus), at day 1 and 600 mg/m2 continuos infusion on day 1-2. All repeated every 2 weeks / Cisplatin, 50 mg/m2 on day 1, then De Gramont schedule on day 1-2: levofolic acid, 100 mg/m2 and 5-FU, 400 mg/m2 (bolus), at day 1 and 600 mg/m2 continuos infusion on day 1-2. All repeated every 2 weeks Progressive Disease 2.0 / 2.0
Jul 13 Gemcitabine 1000 mg/m2 weekly for 3 wk; every 4 wk for six cycles Progressive Disease 4.0
Jun 13 pimasertib and Gemcitabine Gemcitabine 1000 mg/m2 weekly (7 of 8 wks in cycle 1, then 3 of 4 wks in subsequent cycles) and 60 mg pimasertib or placebo twice a day / Gemcitabine 1000 mg/m2 weekly (7 of 8 wks in cycle 1, then 3 of 4 wks in subsequent cycles) and 60 mg pimasertib or placebo twice a day Stable Disease 1.0 / 1.0

Sample ID:     Histology:     Tumor Type: Engrafted Tumor     Passage:     Platform: